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http://dx.doi.org/10Aging in the hematopoietic system and the stem cell niche contributes to aging-associated
phenotypes of hematopoietic stem cells (HSCs), including leukemia and aging-associated im-
mune remodeling. Among others, the DNA damage theory of aging of HSCs is well estab-
lished, based on the detection of a significantly larger amount of gH2AX foci and a higher
tail moment in the comet assay, both initially thought to be associated with DNA damage
in aged HSCs compared with young cells, and bone marrow failure in animals devoid of
DNA repair factors. Novel data on the increase in and nature of DNA mutations in the he-
matopoietic system with age, the quality of the DNA damage response in aged HSCs, and
the nature of gH2AX foci question a direct link between DNA damage and the DNA damage
response and aging of HSCs, and rather favor changes in epigenetics, splicing-factors or
three-dimensional architecture of the cell as major cell intrinsic factors of HSCs aging. Aging
of HSCs is also driven by a strong contribution of aging of the niche. This review discusses the
DNA damage theory of HSC aging in the light of these novel mechanisms of aging of
HSCs. Copyright  2016 ISEH - International Society for Experimental Hematology. Pub-
lished by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).Hematopoiesis, hematopoietic stem cells, and aging of
hematopoietic stem cells
The mammalian blood system consists of many distinct
types of differentiated cells with specialized functions
like erythrocytes, platelets, T and B lymphocytes, myeloid
cells, mast cells, natural killer cells, and dendritic cells.
Many of these mature blood cells are short-lived and,
thus, need to be replaced at a rate of more than one million
cells per second in the adult human [1]. This continuous
replenishment depends on the activity of hematopoietic
progenitor cells (HPCs) and, ultimately, hematopoietic
stem cells (HSCs). HSCs are defined functionally by their
ability to self-renew, as well as to differentiate into more
mature progenitor cells and, therefore, to provide long-
term reconstitution potential of the blood in lethally irradi-
ated recipients over serial transplantation experiments.
HSCs were first described in the 1960s by Becker [2], Sim-: Hartmut Geiger, Institute for Molecular Medicine,
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.1016/j.exphem.2016.06.253inovitch [3], Till and McCulloch [4], and Wu [5] as a pop-
ulation of bone marrow (BM) cells capable of forming
myelo-erythroid colonies in the spleens of irradiated recip-
ient mice. Within these colonies a very small subset of cells
displayed the ability to self-renew and to differentiate into
all types of blood cells. HSCs reside predominantly in the
BM at a frequency of 2 to 5 cells in 105 total BM cells.
Phenotypically, HSCs can be purified to near homogeneity
using combinations of cell surface marker staining or dye
efflux properties with fluorescence-activated cell sorting.
Common marker combinations for long-term (LT)-HSCs
are Lin– (lineage-negative), Sca-1þ, c-Kitþ, CD34,
Flk2 or side population (high Hoechst efflux), Lin,
Sca-1þ, and c-Kitþ. SLAM family markers (CD150þ,
CD48, CD41) can be used to further distinguish myeloid
biased LT-HSCs [6–8].
The number and potential of HSCs are controlled via
complex regulatory mechanisms involving tight molecular
and cellular control of quiescence (G0 state of the cell
cycle), self-renewal (maintenance and expansion), differen-
tiation (production of mature blood cells), apoptosisatology. Published by Elsevier Inc. This is an open access article under the
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cell architecture. Under steady-state conditions, HSCs are
a largely quiescent, slowly cycling cell population, where
only 8% of cells enter the cell cycle per day [9]. However,
in response to stress, HSCs exit quiescence, expand, and
differentiate. The mostly quiescent status of HSCs is thought
to be a protective mechanism against endogenous stress
caused by reactive oxygen species and DNA replication
[10]. Quiescence is different from terminal differentiation,
senescence, and apoptosis because it is reversible and func-
tionally unlike cell cycle arrest. When quiescence is disrup-
ted, HSCs might display premature exhaustion, impaired
self-renewal, and loss of repopulating capacity [11,12].
The balance between quiescence and proliferation is usually
strictly controlled (positively as well as negatively) by the
intrinsic and extrinsic (niche) mechanisms of HSCs.
Contrary to a common assumption that cell loss is tightly
associated with aging, the number of phenotypic HSCs actu-
ally increases in both mice and humans [13,14]. There are
two- to tenfold more HSCs present in the aged BM than in
youngmarrow [13,15,16].Under stress, as in serial transplan-
tation assays, for example, aged HSCs exhibit a diminished
regenerative potential as consequence of a lower long-term
self-renewal capacity [17–19]. Aged HSCs also present
with heightened replicative stress on cycling and decreased
ribosomal biogenesis [20]. Additionally, their ability to
home to the BM is reduced by a factor of 2 [21]. Furthermore,
young and aged HSCs occupy distinct niches within the BM
as seen in their localization relative to the endosteum [22].
Aged HSCs exhibit impaired adhesive properties to stroma
cells and, in turn, can be better mobilized into the blood
compared with young HSCs [22]. Genomewide expression
studies comparing young and aged HSCs have identified a
general downregulation of genes involved in lymphopoiesis
and an upregulation of myeloid genes in aged HSCs, which
is consistent with their myeloid bias [23]. Clinically, aging
of the hematopoietic system is correlated to anemia,
decreased competence of the adaptive immune system, and
increased incidence of myeloid diseases (reviewed byGeiger
et al. [24]). These aging-associated changes can be attributed
at least in part to aging of HSCs. Aged HSCs are deficient in
their ability to support erythropoiesis and exhibit a markedly
decreased output of cells from the lymphoid lineage, whereas
the myeloid lineage output is maintained or even increased
compared with young HSCs. Recent exciting developments
in the field, driven primarily by large-scale high-throughput
sequencing approaches to human blood cells, suggest a high-
ly polyclonal hematopoiesis in young individuals that is
transformed into clonal hematopoiesis on aging, starting at
the age of 70. This shift, from around 1,000 active HSCs to
a few active clones, might also be an additional driver for
the development of hematologic diseases [25], as mutations
in genes associated with aging-associated leukemia, such
as DNMT3A, TET2, JAK2, ASXL1, SF3B1, and SRSF2,
have been found to be associated with clonality [26–28].Finally, aged HSCs present with increased activity of the
cell division control protein 42 (CDC42), a small Rho
GTPase. The increased activity of CDC42 leads to loss of
cell polarity in aged HSCs involving tubulin, CDC42, and
the random nuclear distribution of acetylated H4K16 [29].
Activated levels of Cdc42 activity are causative for aging
of murine HSCs [29]. In addition, epigenetic programs that
maintain HSC function in young decline with age, demon-
strated by changes in DNA methylation patterns on HSC ag-
ing, for example [23,30].DNA damage in aging of HSCs
A controversially discussed cell-intrinsic factor driving HSC
aging is DNA damage. HSCs are responsible for maintain-
ing tissue homeostasis throughout a lifetime. It is therefore
critical for HSCs to maintain their genomic integrity to
reduce the risk of either BM failure or transformation. The
paradigm of the DNA damage theory of stem cell aging
states that aging-associated changes in the DNA repair sys-
tem in HSCs, together with changes in cell cycle regulation
caused by increased DNA damage with age [31,32], are
thought to result in elevated DNA mutations, which then
causally contribute to the decrease in HSCs function with
age. The paradigm is in part based on the finding that
mice lacking a distinct set of DNA damage repair proteins
display reduced function of HSCs, including an impaired re-
populating potential and an overall depletion of the HSC
pool [32–41]. In contrast, in ‘‘naturally’’ aged mice, there
is actually an expansion of the number of phenotypic stem
cells as described above and not a depletion of the HSCs.
DNA damage constantly arises from DNA replication er-
rors, spontaneous chemical reactions and assaults by
external or metabolism-derived agents. It has been esti-
mated that a single cell might undergo up to 100,000
DNA lesions per day. Endogenous sources for DNA dam-
age include replication and recombination errors (error
rate: 1010/bp), spontaneous hydrolysis, and reactive me-
tabolites created as a by-product of cellular metabolism
like reactive oxygen species (ROS) [34]. These events
and metabolites can cause abasic sites, base deamination,
8-oxoguanine lesions, base oxidations, and a variety of
DNA strand breaks. DNA damage can also be induced by
exogenous factors, such as mutagens present in the environ-
ment, ultraviolet light from the sun, chemicals, X-rays, and
gamma irradiation as well as chemotherapeutic drugs
causing base modifications, interstrand crosslinks, and
single- and double-strand breaks. The most severe forms
of DNA damage are DNA double-strand breaks (DSBs),
which arise at an estimated frequency of 10 DSBs/cell/
day. These breaks can be intentional in the case of V(D)J
recombination and class switch in B lymphocytes or acci-
dental and unintentional. DSBs arise from ROS, gamma
irradiation, mechanical stress, defective telomere process-
ing, chemotherapeutic drugs, and replication fork collapse.
897B.M. Moehrle and H. Geiger/ Experimental Hematology 2016;44:895–901DNA damage, regardless of which type, leads to a
cascade of cellular events known as the DNA damage
response (DDR). The single components of these cascades
can be classified into four functional groups: damage sen-
sors, signal transducers, repair effectors, and arrest or death
effectors. The outcome of DNA damage for the cell is vari-
able and depends on potency of the damage, cell type, speed
of DNA repair, p53 activation, and cell cycle stage of the cell
[42,43]. The first step after a DNA DSB occurs involves pro-
teins sensing the damage and activating the DDR. After the
recognition of a DNADSB, transducer proteins become acti-
vated, and signaling cascades are set in motion. ATM (ataxia
telangiectasia mutated) and ATR (ATM and Rad3-related)
are the main transducer proteins and, once activated, pro-
mote the DDR through phosphorylation-dependent recruit-
ment of additional factors to sites of DNA DSBs. A very
important modification at DSBs is the phosphorylation of
histone H2AX, referred to as gH2AX. The DNA around
the phosphorylated form of the histone becomes less
condensed, and a cascade of effector protein assembly is
initiated. Activation of downstream targets of ATM
(including Chk2 and subsequently p53), as well as ATR
signaling (leading to Chk1 and CDC25A phosphorylation),
can result in various different cellular outcomes like transient
cell cycle arrest, apoptosis, senescence, or differentiation.
During transient cell cycle arrest, repair processes are
initiated [44–46]. In case of DNA DSBs, two distinct repair
pathways are usually activated, homologous recombination
(HR) and non-homologous end joining (NHEJ). Because
of the end-processing of DNA strands and a subsequent
direct ligation of the break, NHEJ generally leads to small
deletions and is thus thought to be error-prone and to result
in DNA mutations [47]. In contrast, HR, which is based on
a homologous DNA template (sister chromatid or homolo-
gous chromosome), is seen as an error-free process with
respect to DNA mutations. HSCs mostly residing in G0
phase of the cell cycle are thought to be susceptible to un-
dergo the error-prone NHEJ pathway to repair DNA DSBs
arising from low-dose irradiation, thus making the cells
vulnerable to acquiring mutations via faulty NHEJ [48]. In
contrast to this observation, Insinga et al. showed an up-
regulation of p21 in HSCs after irradiation followed by
cell cycle entry that could enable the cells to use the error-
free HR pathway to repair DNADSBs [49]. More committed
progenitor cells, however, underwent p53-dependent
apoptosis because of irradiation, illustrating the difference
in DNA damage response between stem cells and their prog-
eny. Additionally, Beerman et al. [50] found that quiescent
HSCs acquire DNA damage on aging, but when these cells
start to cycle, the damage becomes repaired.
Alternatively, if repair is impossible, cells undergo
apoptosis, senescence, or in case of stem cells, also differ-
entiation. Published data indicate that DNA DSBs are very
potent inducers of cellular senescence, implying that persis-
tent DDR signaling confers senescent growth arrest [51,52].In addition, differentiation in response to DNA damage oc-
curs in various tissues including HSCs, melanocytic stem
cells, and embryonic stem cells [45,46,53]. In HSCs,
DNA damage induced by telomere attrition or DNA
DSBs leads to an upregulation of the transcription factor
Batf, resulting in induction of lymphoid differentiation of
HSCs [46]. DNA damage induces apoptosis by both p53-
dependent and p53-independent pathways. In lymphocytes
and germ cells, apoptosis even represents the primary
response to DNA damage [54]. In the context of HSCs, pre-
mature differentiation, senescence, and apoptosis as
possible consequences of DNA damage are double-edged
swords. They can be beneficial by removing damaged cells,
but might at the same time lead to depletion and exhaustion
of the stem cell pool.
What kind of phenotype in the hematopoietic system is
present in animals with genetic deletions in genes linked to
DNA damage repair and the DDR? For example, mice
deleted for the ATM gene exhibit increased IR sensitivity
and decreased T-cell numbers. HSCs from these mice
have increased ROS levels and present with a decrease in
number and function on aging, leading to progressive BM
failure [34,55,56]. Knockout of any component of the
MRN complex, as well as deletion of BRCA2, results in
embryonic lethality. A hypomorphic Rad50k22m mutation
in mice leads to early death accompanied by B-cell
lymphoma and BM failure. This is due mostly to p53-
dependent apoptosis and loss of HSC function [57]. Inacti-
vation of genes involved in NHEJ illustrated their essential
function in lymphocyte development, as components of
NHEJ are critical for V(D)J recombination. Mice with a Li-
gIVy288c hypomorphic mutation are immunodeficient and
display severe HSC defects, such as impaired repopulating
potential and decreased self-renewal [36]. Mice devoid of
Ku70 or Ku80 end-binding proteins exhibit self-renewal de-
fects, impaired differentiation and proliferation potential, as
well as increased apoptosis within the HSC compartment
[32,58]. In a mouse model in which phosphorylation sites
of DNA-PKcs were mutated (3A mutation, 3-alanine
substitution of Thr2605, 2634 þ 2643) called
DNA-PKcs3A/3A, BM failure and loss of HSCs in fetal liver
could be observed. This impairment of HSC proliferation is
caused by p53-dependent apoptosis resulting from severe
DNA damage. Because p53 is also involved in the DDR,
it is interesting to note that mice with varying p53 activities
display distinct hematopoietic problems. Reduced p53 ac-
tivity in heterozygous p53þ/ mice is accompanied by an
increase in HSC proliferation. A p53 hypomorphic muta-
tion (p53þ/m) displaying higher p53 activity than in wild-
type mice presented with decreased HSC frequency,
repopulating capacity, and proliferation [59]. In summary
though, mutations in most of the genes linked to DNA dam-
age response so far did not result in the ‘‘aging-character-
istic’’ initial expansion of the number of phenotypic
HSCs, rendering a central role for these genes and the
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of the hematopoietic system not likely.
Analyses of young and aged HSCs with respect to
changes in the frequency of DNA damage and the fre-
quency of DNA mutations (comet assay, gH2AX foci,
DNA mutation frequency, loss of heterozygosity assays) re-
vealed a minor increase in these parameters on aging in
steady-state hematopoiesis [32,50,60,61]. Elevated levels
of gH2AX foci in aged HSCs are also associated with repli-
cation stress, as well as ribosomal biogenesis stress, and
therefore might not be unequivocally associated with
DNA damage (Table 1) [20].
In general, aged murine hematopoietic cells (either
BM or peripheral blood, and independent of the type of
mutation assay) exhibit a two- to threefold increase in
mutation frequency in hematopoiesis compared with
young cells [61–63], which is also in the range of changes
in mutation frequency recently reported for human he-
matopoietic cells, determined via deep-sequencing ap-
proaches [26–28,64–67]. Interestingly, although the
overall increase in mutation frequencies in blood cells
was found to be again in the range of two- to threefold,
a set of genes including DNMT3A, TET2, JAK2,
ASXL1, SF3B1, or SRSF2 were frequently mutated, in
both aging-associated leukemia and aging-associated
changes in clonality. These genes function primarily in
epigenetic regulation and splicing but are usually not
associated with DNA repair or the DDR, implying that
these pathways are not selected on aging of HSCs.
Although these data in aggregation confirm a mild
two-to threefold aging-associated increase in the mutation
frequency in hematopoiesis, the increase is linear and not
exponential with respect to age, rendering a cause–conse-
quence relationship to the exponential increase of
leukemia on aging unlikely. Modeling of aging of HSCs
populations based on evolutionary theories also indicates
that accumulation of genetic changes within HSCs is not
sufficient to alter selectivity and fitness of HSCs, andTable 1. DNA damage accumulation on aging in HSCs
Increased DNA damage and DNA mutations on aging in HSCs
Yes
Accumulation of gH2AX foci, indicative of persistent DNA DSBs [14]
Comet assay experiments in aged HSCs revealed a twofold increase in
DNA damage level in steady state [50,61]
Mutation frequency in human and murine BM is increased twofold
upon aging [26,61,64,65]
Incidence of leukemia increases dramatically upon aging [77,79,80]
Mouse models with altered DNA damage response genes exhibited BM
failure and depletion of the HSC pool [32,34,36,55–59,81]identified non-cell autonomous mechanisms, also known
as changes in the niche, as the major selective driving
force for aging-associated leukemia [68]. Such conclu-
sions are also supported by the observation that while a
twenty-twofold increase in the mutational load [69] initi-
ated cancer in the presence of a mutator gene type setting
[70–72], a modest two- to threefold increase in mutational
load in hematopoiesis in the context of the AML-ETO
oncogene did not result in leukemia initiation [73] in
mice in vivo. Finally, novel data from our laboratory indi-
cated that the quality of the DDR in HSCs does not
change on aging. HSCs, both young and old, enter the
cell cycle in vivo upon DNA damage, without initiating
a strong G1–S cell cycle arrest as reported for fibroblasts
[61]. They also do not present with a marked difference in
apoptosis in vivo on induction of DSBs. Second, in
response to irradiation, both young and aged HSCs re-
sponded functionally identically, as revealed in competi-
tive transplantation–irradiation–recovery experiments, in
which young and aged HSCs directly competed in the
same recipient animal in vivo in response to total-body
irradiation [61]. Third, there was a significant decrease
in the mutation frequency in both young and aged BM
4 months after total-body irradiation, and aged animals
presented with a mutation frequency similar to that of
young animals [61]. One explanation for such observa-
tions might be that deeply quiescent HSCs are the ones
with few mutations because of their small number of
cell divisions [74], whereas HSCs that already underwent
a larger number of divisions, and thus most likely have a
low level of mutations, instead apoptose or differentiate in
response to irradiation. Therefore, it is possible that the
deeply quiescent HSCs survive irradiation and support he-
matopoiesis after other HSCs have been eliminated by
irradiation [10], further indicating the resilience of the he-
matopoietic system to acquire a large number of mutations
in HSCs that might directly contribute to aging of HSCs
and leukemia.and the hematopoietic system contribute to aging of HSCs
No
gH2AX foci can also indicate replication and ribosome biogenesis
stress in aged HSCs [20]
In aged hair follicle stem cells, gH2AX foci are associated with
persistent chromatin alterations but not DNA DSBs [78]
DNA damage level decreased on cell cycle entry of aged HSCs [50]
Mutation frequency in aged BM decreases upon DNA damage [61]
In aging-associated leukemia, only very few driver mutations could
be identified [27,28,66,67]
In normal aging, there is an increase in the number of HSCs [13,14]
899B.M. Moehrle and H. Geiger/ Experimental Hematology 2016;44:895–901Perspective
Because the accumulation of DNA mutations in HSCs on
aging might not be linked directly to the functional decline
of HSCs with age and an aging-associated exponential in-
crease in the incidence of leukemia, what other mechanisms
might contribute to these phenotypes? It could already be
shown that aging of the HSC niche and environment plays
an important role in selecting and expanding normal and
preleukemic HSC and HPC clones on aging [75,76].
Thus, the concept of adaptive landscapes recently has
been developed [77]. In this concept, the niche environment
of HSCs changes on aging, influencing the functionality of
HSCs. The mutations acquired over time might not influ-
ence the HSC per se. In addition to extrinsic factors,
intrinsic alterations that are not mutations in DNA might ul-
timately contribute to HSC aging. We recently reported that
HSCs change their polarity on aging, in both the cytoplasm
and the nucleus. It thus might be possible that changes in
the general architecture of the cell might also contribute
to HSC aging. Changes in the three-dimensional arrange-
ment of epigenetic marks and structural proteins might in-
fluence cell divisions in a way that reduces potential in
daughter stem cells, for example, contributing to intrinsic
HSC aging. In summary, multiple mechanisms might
contribute to aging of HSCs and ultimately depend on the
interplay between extrinsic and intrinsic cell factors.Acknowledgments
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